Inotec sponsored the study to investigate the impact of NATROX® on previously non healing DFUs. Held across 19 sites in the USA, the trial involved 145 patients with 54% over age 65. The study’s Principal Investigator, Dr. Thomas Serena, is an internationally recognized expert in wound healing. Dr. Serena is former President of the American Professional Wound Care Association and currently CEO of the SerenaGroup®, a leading provider of wound care. Eligible patients had a chronic wound for an average of 23-24 weeks before entering the 12-week therapy period, and over half the participants in the NATROX® group had a history of prior amputation. It is worth noting, the study continuing despite new COVID-19 protocols indicates the ease and simplicity of treatment … read more
Tag: Oxygen Wound Therapy
NATROX® Symposium at EWMA 2018
Inotec AMD hosted a well-attended symposium at the 2018 EWMA Conference in Krakow (Poland).
The Symposium focused on the vital role of oxygen in chronic wound healing and the importance of the Inotec’s NATROX® Oxygen Wound Therapy supported by three key speakers of the calibre of Paul Hayes, Hanna Kaufman and Thomas Serena.
Paul Hayes, vascular surgeon from the UK, discussed the role of topical oxygen in wound healing presenting the latest evidence on the matter. Hanna Kaufman, orthopaedic surgeon from Israel, shared the intriguing results of her 99-patient NATROX® study on non-healing wounds. Thomas Serena, founder and medical director of SerenaGroup in the US, explored the future of oxygen wound therapy.
NATROX® Oxygen Wound Therapy is an innovative, simple and easy-to-use device that has been clinically proven to deliver 98% pure humidified oxygen direct to the wound bed.